Trial Profile
HOG LUN 05-99: HOG LUN05-99: Paclitaxel plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 30 Jun 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.
- 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
- 23 Jan 2008 The expected completion date for this trial is now .